TAK-390MR Phase 3 Data Presented At Digestive Disease Week
May 22nd 2008Drug InformationAcid Reflux/GERD
TAP Pharmaceutical Products Inc. have reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE. The data were presented at the Digestive Disease Week (DDW) annual meeting in San Diego.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
